Skip to main content

Table 3 Efficacy outcomes after one year of follow-up after seasonal influenza vaccination in patients with COPD

From: Seasonal influenza vaccination in patients with COPD: a systematic literature review

Reference Country Study design Influenza season Vaccine type n Efficacy outcome Comment
Kositanont et al., 2004 [40] Thailand RCT 1997–1998a    ARI with confirmed influenza (incidence (n/N)) Study conducted in non-epidemic years. Most circulating A/H3N2 viruses among patients with acute respiratory infections matched the vaccine strain.
TIV 61 8.2% (5/61)
Placebo 62 27.4% (17/62)
Wongsurakiat et al., 2004 [35] Thailand RCT 1997–1998a    IR of influenza-related ARI episodes
TIV 62 6.8 per 100 py
Placebo 63 28.1 per 100 py (p = 0.0005)
   IR of outpatient episodes
TIV 62 3.4 per 100 py
Placebo 63 19.8 per 100 py (p = 0.009)
   IR of hospitalisation episode
TIV 62 3.4 per 100 py
Placebo 63 8.3 per 100 py (p = 0.3)
   IR of mechanical ventilation episode
TIV 62 0
Placebo 63 5.0 per 100 py (p = 0.1)
  1. ARI acute respiratory illness, IR incidence rate, n number of subjects, py person years, RCT randomised controlled trail, TIV trivalent iinfluenza vaccine, Placebo Vitamin B1 injection, n/N number of subjects with the outcome indicated over the total number of subjects
  2. Wongsurakiat et al., 2004 and Kositanont et al., 2004 describe the same RCT
  3. aEnrolment between June 1997 – November 1998, subjects were followed for one year after vaccination